Clinuvel Pharmaceuticals Limited Stock Xetra
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
03:56:34 28/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 5.737 EUR | 0.00% |
|
0.00% | - |
| Market Cap | 463M 333M 286M 268M 245M 462M 31.8B 3.17B 1.24B 16.03B 1.25B 1.22B 53.05B | P/E 2026 |
15.4x | P/E 2027 * | 12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 210M 151M 130M 122M 111M 210M 14.44B 1.44B 563M 7.28B 568M 556M 24.09B | EV / Sales 2026 |
5.51x | EV / Sales 2027 * | 1.7x |
| Free-Float |
83.79% | Yield 2026 * |
0.67% | Yield 2027 * | 0.87% |
Last Transcript : Clinuvel Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 380M | |
| -0.30% | -1.62% | +38.55% | -2.13% | 81.36B | |
| -5.14% | +5.77% | +461.81% | +23.88% | 59.75B | |
| +0.84% | +4.44% | -19.19% | -35.11% | 59.19B | |
| +0.76% | +3.53% | +0.08% | +36.18% | 53.33B | |
| +0.41% | +1.84% | +10.29% | +170.02% | 49.09B | |
| -0.16% | +3.22% | +62.25% | -16.53% | 32.66B | |
| -0.57% | +0.19% | +50.24% | +96.61% | 25.97B | |
| -2.00% | +9.52% | +12.38% | +218.34% | 24.39B | |
| +0.78% | +0.47% | +61.53% | +123.40% | 16.91B | |
| Average | -0.54% | +0.16% | +75.33% | +68.30% | 44.74B | |
| Weighted average by Cap. | -0.68% | -1.01% | +86.39% | +46.77% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 99.21M 71.36M 61.26M 57.35M 52.51M 98.92M 6.82B 679M 265M 3.43B 268M 262M 11.37B | 105M 75.24M 64.59M 60.47M 55.37M 104M 7.19B 716M 280M 3.62B 282M 276M 11.99B |
| Net income | 35.72M 25.69M 22.05M 20.65M 18.91M 35.62M 2.45B 245M 95.58M 1.24B 96.46M 94.38M 4.09B | 37.66M 27.09M 23.25M 21.77M 19.93M 37.55M 2.59B 258M 101M 1.3B 102M 99.51M 4.32B |
| Net Debt | -253M -182M -156M -146M -134M -252M -17.36B -1.73B -676M -8.75B -682M -668M -28.96B | -285M -205M -176M -165M -151M -284M -19.55B -1.95B -762M -9.85B -769M -752M -32.61B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
